Newsmeme!
Discover News you didn't know existed
SMT Research and Development, Ltd., a privately held company, announced that it has completed its first two clinical cases using the Shimon Embolic Filter [SHEF] (TM). SMT R&D developed a novel technology for brain protection (Neuroprotection) from stroke complication hazards arising from invasive cardiology procedures and heart surgery. The rate of stroke and silent brain damage is the leading ...
Gettysburg College men's basketball player Cory Weissman continues to rehabilitate after a brain hemorrhage almost took his life in the spring. Gettysburg College basketball player Cory Weissman shoots the ball along the sidelines while his teammates practice.
Deep Brain Stimulation (DBS), a new treatment being offered at Geisinger Medical Center (GMC) and Geisinger Wyoming Valley Medical Center (GWV), can dramatically reduce symptoms of movement disorders. Parkinson's disease and other movement disorders can be incredibly difficult for patients to manage, and medical treatment options can be limited and/or ineffective. "Deep Brain Stimulation is a ...
Send information about free or low-cost health-related events open to the public one week ahead of publication. Information can be e-mailed to jmorreale@bradenton.com. Listings are due 10 days in advance.
Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment ...
Feb. 4: He emerged from the car accident alive but alone, there and not there: a young man whose eyes opened yet whose brain seemed shut down. For five years he lay mute and immobile beneath a diagnosis — “vegetative state” — that all but ruled out the possibility of thought, much less recovery.
Experts said a finding could raise ethical questions about consulting severely disabled patients on care.
PARIS and LAUSANNE, Switzerland, February 4 /PRNewswire/ -- Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22 ...
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
PARIS & LAUSANNE, Switzerland----Regulatory News:
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |